Highest-materiality recent filing
Boston Scientific cyber incident to materially hit Q3 and FY 2026 results; will miss guidance
Incident detected Aug 25, 2026; no evidence of ongoing unauthorized access as of Sept 7, 2026.
Boston Scientific discloses cybersecurity incident disrupting global operations
Cybersecurity incident identified Aug 25, 2026 affecting certain IT systems; global operations disrupted.
Boston Scientific Q2 net sales $5.44B (+7.5% reported); adjusted EPS $0.86 beats guidance
Net sales $5.442B, up 7.5% reported (guidance 5.5-7.5%); adjusted EPS $0.86 (guidance $0.82-$0.84).
Boston Scientific approves 2026 restructuring plan with $700M-$800M pre-tax charges
Board approved 2026 Restructuring Plan on July 21, 2026; expected to be substantially completed by end of 2029.
Boston Scientific enters $2B accelerated share repurchase, expects $0.02 EPS accretion in FY2026
ASR with JPMorgan for $2B; receives ~30.4M shares upfront at $52.68 (80% of repurchase price).
Boston Scientific invests $1.5B for ~34% stake in MiRus, gains option to acquire TAVR system for $3B
Paid $1.5B cash for 33.75% non-voting equity in MiRus; exclusive call option to buy TAVR business for $3.0B upon clinical/regulatory milestones.
Boston Scientific Q1 2026 net sales $5.20B (+11.6% reported), adj EPS $0.80 (guidance $0.78-$0.80)
GAAP EPS $0.90 vs $0.45 YoY; adjusted EPS $0.80 vs $0.75 YoY, at top of guidance.
Boston Scientific reports positive HI-PEITHO and CHAMPION-AF trial results
HI-PEITHO: EKOS plus anticoagulation reduced primary endpoint events by 61% vs anticoagulation alone (4.0% vs 10.3%, P=0.005).
Boston Scientific enters $11B credit facilities; $8B committed for Penumbra acquisition
$3.0B revolving credit agreement matures Feb 2031 with two one-year extension options.
Boston Scientific boosts buyback by $4B to $5B; appoints two new directors
Board approved additional $4.0B stock repurchase authorization, total available now $5.0B.
Boston Scientific reports Q4 and full year 2025 results, announces acquisitions
Q4 2025 net sales $5.286B, up 15.9% reported; GAAP EPS $0.45, adjusted EPS $0.80.
Boston Scientific to acquire Penumbra for ~$14.5B enterprise value ($374/share)
Deal consideration: ~73% cash, ~27% stock; $374 per Penumbra share; enterprise value ~$14.5B.
Penumbra shareholders elect cash ($374/share) or stock (3.8721 BSX shares/share); proration targets 73.26% cash, 26.74% stock.
GAAP net income $755M ($0.51 EPS) vs $469M ($0.32) a year ago; adjusted EPS $0.75 vs $0.63.
GAAP EPS $0.53 ($797M net income) vs $0.22 a year ago; adjusted EPS $0.75 vs guidance $0.71-0.73.
Discontinuing worldwide sales of ACURATE neo2 and ACURATE Prime Aortic Valve Systems; no longer pursuing U.S. FDA or other approvals.
Boston Scientific Q1 sales $4.66B (+20.9% reported, +18.2% organic), EPS beat guidance
GAAP EPS $0.45 (up 36% YoY); adjusted EPS $0.75, above guidance $0.66-0.68.
Boston Scientific CFO Dan Brennan to retire; Jon Monson named successor effective June 30, 2025
Dan Brennan retires as EVP & CFO effective June 29, 2025; will remain senior advisor to October 3, 2025.
Boston Scientific subsidiary prices €1.5B senior notes to refinance 2025 maturity
AMS Europe issued €850M 3.000% notes due 2031 and €650M 3.250% notes due 2034.
Q4 net sales $4.561B (+22.4% reported, 19.5% organic); GAAP EPS $0.38, adjusted EPS $0.70 vs guidance $0.64-0.66.
Boston Scientific reaches preliminary settlement of derivative lawsuits over LOTUS Edge recall
On January 8, 2025, a U.S. district court granted preliminary approval of a settlement of two shareholder derivative actions related to the LOTUS Edge recall.
Boston Scientific completes $3.7B acquisition of Axonics; enters sacral neuromodulation market
Purchase price $71/share, equity value $3.7B, enterprise value $3.3B net of cash.
Boston Scientific Q3 net sales $4.209B (+19.4% reported), adj. EPS $0.63 vs $0.50 YoY
Net sales $4.209B, up 19.4% reported, 18.2% organic; beat guidance of 13-15%.
Q2 net sales $4.120B, up 14.5% reported (16.1% operational, 14.7% organic); GAAP EPS $0.22, adjusted EPS $0.62 vs guidance $0.57-$0.59.
GAAP net income $495M ($0.33 EPS) vs guide $0.29-0.31; adjusted EPS $0.56 vs $0.47 YoY and $0.50-0.52 guide.
Boston Scientific gets FTC Second Request for Axonics merger; closing expected H2 2024
FTC issued Second Request under HSR Act on April 3, 2024, extending waiting period.
Boston Scientific issues €2B in senior notes to finance Axonics acquisition
AMS Europe, a Boston Scientific subsidiary, issued €750M 3.375% notes due 2029 and €1.25B 3.500% notes due 2032.
BSX Q4 sales $3.73B (+14.9% reported), adj EPS $0.55; FY2024 adj EPS guidance $2.23-$2.27
Q4 net sales $3.725B (+14.9% reported); GAAP EPS $0.34, adj EPS $0.55 beat guidance ranges.
Purchase price of $71 per share cash; equity value ~$3.7B, enterprise value ~$3.4B.
Boston Scientific to acquire Axonics for $71.00 per share in cash
Each Axonics share will be converted into $71.00 in cash, without interest.
Boston Scientific beats Q3 estimates; raises FY 2023 adjusted EPS guidance to $1.99-2.02
Q3 net sales $3.527B (+11.2% reported, +10.2% organic); beat guidance of 8.5-10.5% reported and 7-9% organic.
Boston Scientific Q2 beats: $3.599B revenue (+11% reported), adj. EPS $0.53 vs guidance $0.48-$0.50
Revenue $3.599B, +11% reported, +11.6% organic; beat guidance of 6.5-8.5% reported.
On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027.
Jonathan Monson, who currently serves as Senior Vice President, Investor Relations, has been promoted to Executive Vice President and Chief Financial Officer of the Company effective as of June 30, 2025
On April 23, 2025, Boston Scientific Corporation (the “Company”) announced that Daniel J. Brennan has decided to retire from his role as Executive Vice President and Chief Financial Officer of the Company effective as of June 29, 2025
Charles J. Dockendorff informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders
appointed David C. Habiger, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective July 30, 2024.
appointed Cheryl Pegus, MD, MPH, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective May 8, 2024.
Also on January 26, 2024, the Board appointed Emily Woodworth (Collins), age 46, as Senior Vice President, Global Controller and Chief Accounting Officer, effective March 1, 2024.
On January 26, 2024, the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”) appointed Jonathan Monson as Senior Vice President, Investor Relations, effective March 1, 2024.
On November 16, 2023, Nelda J. Connors informed Boston Scientific Corporation (the “ Company ”) that she will not stand for re-election at the Company’s 2024 Annual Meeting
On November 16, 2023, David J. Roux informed the Company that he will not stand for re-election at the Company’s 2024 Annual Meeting
appointed each of Jessica L. Mega, MD, MPH and Susan E. Morano to be a director of the Company, to hold office until the next annual meeting of stockholders, in each case, effective June 27, 2023.
appointed each of Jessica L. Mega, MD, MPH and Susan E. Morano to be a director of the Company, to hold office until the next annual meeting of stockholders, in each case, effective June 27, 2023.
Max materiality 0.95 · Median 0.75 · Most common event earnings